Shares of Merck KGaA (OTCMKTS:MKKGY - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $26.43, but opened at $25.66. Merck KGaA shares last traded at $25.64, with a volume of 1,066 shares traded.
Analysts Set New Price Targets
Several analysts have commented on MKKGY shares. Barclays cut shares of Merck KGaA from a "strong-buy" rating to a "hold" rating in a research note on Tuesday. Zacks Research raised shares of Merck KGaA to a "hold" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold".
Check Out Our Latest Stock Report on Merck KGaA
Merck KGaA Price Performance
The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.83 and a current ratio of 1.31. The stock has a market cap of $17.01 billion, a price-to-earnings ratio of 11.06, a price-to-earnings-growth ratio of 3.19 and a beta of 0.91. The business's fifty day simple moving average is $25.87 and its 200 day simple moving average is $26.95.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.06. Merck KGaA had a net margin of 13.49% and a return on equity of 9.81%. The firm had revenue of $6.11 billion for the quarter, compared to analyst estimates of $5.34 billion. Research analysts predict that Merck KGaA will post 1.87 EPS for the current fiscal year.
About Merck KGaA
(
Get Free Report)
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Recommended Stories
Before you consider Merck KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.
While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.